Organigram Global Inc.
OGIHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 21, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Oct 20
Part of the healthcare sector, Organigram Global Inc. (OGI) is listed under Drug Manufacturers - Specialty & Generic. The $132.1M market capitalization puts OGI squarely in micro-cap range for its industry. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands.
Market Cap
$132.1M
Beta
1.91
P/E (TTM)
2.18
P/E (Fwd)
39.04
EPS (TTM)
$0.43
EPS (Fwd)
$0.02
ROE
17.6%
ROA
-0.6%
Cash
$11.7M
Total Debt
$31.7M
Free CF
-$1.2M
52W Change
-45.5%
Annual Financials
Cash vs Debt
Where OGI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, OGI finished 17.54% below its 150-day moving average ($1.14) and 23.58% below its 200-day moving average ($1.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OGI overbought or oversold?
At the October 20, 2026 close, OGI's RSI(14) was 28.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Organigram Global Inc. carries $31.7M in total debt against $11.7M in cash reserves — debt is roughly 2.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$1.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 17.6% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $79.2M (2021) to $259.2M (2025), reflecting a 227% increase over the period.
A beta of 1.91 means OGI is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OGI.